Horizon Pharma Ord (HZNP) 18.89 $HZNP
Market Updates on Drugs - Generic Equities -- Mylan, Horizon Pharma, Allergan, and Diplomat Pharmacy
PR Newswire - Fri Jul 15, 6:30AM CDT
On Thursday, July 14, 2016, the NASDAQ Composite ended the trading session at 5,034.06, up 0.57%; the Dow Jones Industrial Average edged 0.73% higher, to finish at 18,506.41; and the S&P 500 closed at 2,163.75, up 0.53%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Allergan PLC (NYSE: AGN), and Diplomat Pharmacy Inc. (NYSE: DPLO). Learn more about these stocks by accessing their free notes at:
AGN: 254.86 (+1.91), DPLO: 35.72 (-0.21), HZNP: 18.89 (-0.40), MYL: 46.74 (-0.05)
Nuvo Pharmaceuticals(TM) Inc. Announces Pennsaid 2% Phase 3 Trial to Support Regulatory Approvals in the E.U., Canada and Australia
CNW Group - Wed Jul 13, 6:30AM CDT
Nuvo Pharmaceuticals Inc. (TSX:NRI) (Nuvo or the Company) today announced it will conduct a new placebo-controlled, multi-centre Phase 3 trial (Trial) in Germany to study Pennsaid 2% for the treatment of acute ankle sprains. Topline results of the Trial are expected to be available in late Q2 or early Q3 2017. The Trial is subject to approval by German regulatory authorities and the ethical review committee. Pennsaid 2% is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of the pain of osteoarthritis of the knee(s). The Trial will be conducted to support regulatory applications for marketing approval of Pennsaid 2% for the treatment of acute pain in the E.U., Canada and Australia. The Company believes that most other jurisdictions will base their marketing approval on existing data, including the current U.S. FDA approval of Pennsaid 2% and will not require additional clinical efficacy data. The Trial will cost approximately CDN$1.5 million spread over the second half of 2016 and the first half of 2017. The Company believes that potential revenue to be generated by the Trial far exceeds its modest cost.
NRI.TO: 6.93 (-0.07), HZNP: 18.89 (-0.40)
Looking for Bargain Stocks? Pick These 5 with Low P/B Ratio
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 9:57AM CDT
The P/B ratio is used to calculate how much an investor needs to pay for each dollar of book value of a stock.
MNK: 67.37 (+0.03), PMC: 26.42 (-0.14), KEP: 27.37 (+0.18), HZNP: 18.89 (-0.40), SEM: 11.27 (-0.23)
Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma
PR Newswire - Fri Jun 17, 7:00AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), and Celator Pharmaceuticals Inc. (NASDAQ: CPXX). Learn more about these stocks by accessing their free trade alerts at:
CPXX: 30.24 (unch), AGN: 254.86 (+1.91), HZNP: 18.89 (-0.40), MYL: 46.74 (-0.05)
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting
PR Newswire - Tue Jun 07, 2:42PM CDT
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
NRI.TO: 6.93 (-0.07), HZNP: 18.89 (-0.40)
Nuvo Pharmaceuticals(TM) Announces Director Election Results of its Annual General Meeting
CNW Group - Tue Jun 07, 2:42PM CDT
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
NRI.TO: 6.93 (-0.07), HZNP: 18.89 (-0.40)
Horizon Pharma plc to Participate in Jefferies 2016 Healthcare Conference
Marketwired - Thu Jun 02, 6:00AM CDT
DUBLIN, IRELAND--(Marketwired - Jun 2, 2016) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that the company will present at the Jefferies 2016 Healthcare Conference at 2 p.m. EDT on June 9, 2016 in New York City, NY.
HZNP: 18.89 (-0.40)
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen/esomeprazole) Delayed Release Tablets
Marketwire Canada - Wed Jun 01, 6:00AM CDT
Will Represent the Fifteenth U.S. Patent Listed in the Orange Book for VIMOVO
HZNP: 18.89 (-0.40), ARZ.TO: 4.56 (-0.07), ARLZ: 3.89 (+0.39)
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 98.20 (+1.20), HZNP: 18.89 (-0.40), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71), ACOR: 25.13 (-0.15), BIOD: 0.41 (-0.03), XNPT: 7.07 (+0.05)
Horizon (HZNP) to Buy Global Rights to Actimmune, Stock Down
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:10AM CDT
Horizon Pharma (HZNP) will acquire global rights to Actimmune from Boehringer Ingelheim. The deal is expected to close by year end.
ANIP: 61.06 (+0.46), HZNP: 18.89 (-0.40), RTRX: 18.17 (+0.24), BMY: 76.19 (+1.38)
Horizon Pharma plc to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim International GmbH
Marketwire Canada - Thu May 19, 6:00AM CDT
Also Licenses Rights to Patents and Pending Applications Covering Methods for Treating Friedreich's Ataxia With Interferon Gamma-1b; Company Currently Owns the Rights to Interferon Gamma-1b Under the Trade Name ACTIMMUNE(R) in the United States, Canada and Japan
HZNP: 18.89 (-0.40)
Horizon Pharma plc to Participate in UBS Global Healthcare Conference
Marketwire Canada - Wed May 18, 4:45PM CDT
DUBLIN, IRELAND--(Marketwired - May 18, 2016) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that Timothy P. Walbert, chairman, president and chief executive officer, will present at the UBS Global Healthcare Conference at 11 a.m. EDT on May 25, 2016 in New York City, NY.
HZNP: 18.89 (-0.40)
Horizon Pharma plc Announces That Marilyn Vetter Honored as a 2016 Healthcare Businesswomen's Association Luminary
Marketwired - Thu May 12, 7:00AM CDT
DUBLIN, IRELAND--(Marketwired - May 12, 2016) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that Marilyn Vetter, vice president, government and public affairs, has been named a 2016 Healthcare Businesswomen's Association (HBA) Luminary. Marilyn will be honored today at the 27th annual Woman of the Year event in New York.
HZNP: 18.89 (-0.40)
Horizon Pharma plc Announces Settlement of PENNSAID(R) (diclofenac sodium topical solution) 2% w/w Patent Litigation With Teligent, Inc.
Marketwire Canada - Thu May 12, 6:00AM CDT
DUBLIN, IRELAND--(Marketwired - May 12, 2016) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that its affiliates have entered into a settlement and license agreement with Teligent, Inc. to resolve pending patent litigation involving PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID® 2%).
HZNP: 18.89 (-0.40), TLGT: 8.29 (+0.17)
Nuvo Pharmaceuticals™ Announces 2016 First Quarter Results
PR Newswire - Wed May 11, 4:00PM CDT
Revenue and gross margin increase - - Nuvo to Host Conference Call/Audio Webcast May 12th at 8:30 a.m. ET -
NRI.TO: 6.93 (-0.07), HZNP: 18.89 (-0.40)
Market Updates on Drugs - Generic Equities -- Mylan, Horizon Pharma, Allergan, and Diplomat Pharmacy
PR Newswire - Fri Jul 15, 6:30AM CDT
On Thursday, July 14, 2016, the NASDAQ Composite ended the trading session at 5,034.06, up 0.57%; the Dow Jones Industrial Average edged 0.73% higher, to finish at 18,506.41; and the S&P 500 closed at 2,163.75, up 0.53%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Allergan PLC (NYSE: AGN), and Diplomat Pharmacy Inc. (NYSE: DPLO). Learn more about these stocks by accessing their free notes at:
AGN: 254.86 (+1.91), DPLO: 35.72 (-0.21), HZNP: 18.89 (-0.40), MYL: 46.74 (-0.05)
Nuvo Pharmaceuticals(TM) Inc. Announces Pennsaid 2% Phase 3 Trial to Support Regulatory Approvals in the E.U., Canada and Australia
CNW Group - Wed Jul 13, 6:30AM CDT
Nuvo Pharmaceuticals Inc. (TSX:NRI) (Nuvo or the Company) today announced it will conduct a new placebo-controlled, multi-centre Phase 3 trial (Trial) in Germany to study Pennsaid 2% for the treatment of acute ankle sprains. Topline results of the Trial are expected to be available in late Q2 or early Q3 2017. The Trial is subject to approval by German regulatory authorities and the ethical review committee. Pennsaid 2% is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of the pain of osteoarthritis of the knee(s). The Trial will be conducted to support regulatory applications for marketing approval of Pennsaid 2% for the treatment of acute pain in the E.U., Canada and Australia. The Company believes that most other jurisdictions will base their marketing approval on existing data, including the current U.S. FDA approval of Pennsaid 2% and will not require additional clinical efficacy data. The Trial will cost approximately CDN$1.5 million spread over the second half of 2016 and the first half of 2017. The Company believes that potential revenue to be generated by the Trial far exceeds its modest cost.
NRI.TO: 6.93 (-0.07), HZNP: 18.89 (-0.40)
Looking for Bargain Stocks? Pick These 5 with Low P/B Ratio
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 9:57AM CDT
The P/B ratio is used to calculate how much an investor needs to pay for each dollar of book value of a stock.
MNK: 67.37 (+0.03), PMC: 26.42 (-0.14), KEP: 27.37 (+0.18), HZNP: 18.89 (-0.40), SEM: 11.27 (-0.23)
Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma
PR Newswire - Fri Jun 17, 7:00AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), and Celator Pharmaceuticals Inc. (NASDAQ: CPXX). Learn more about these stocks by accessing their free trade alerts at:
CPXX: 30.24 (unch), AGN: 254.86 (+1.91), HZNP: 18.89 (-0.40), MYL: 46.74 (-0.05)
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting
PR Newswire - Tue Jun 07, 2:42PM CDT
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
NRI.TO: 6.93 (-0.07), HZNP: 18.89 (-0.40)
Nuvo Pharmaceuticals(TM) Announces Director Election Results of its Annual General Meeting
CNW Group - Tue Jun 07, 2:42PM CDT
Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2016 Annual Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated May 4, 2016 were elected as directors of the Company.
NRI.TO: 6.93 (-0.07), HZNP: 18.89 (-0.40)
Horizon Pharma plc to Participate in Jefferies 2016 Healthcare Conference
Marketwired - Thu Jun 02, 6:00AM CDT
DUBLIN, IRELAND--(Marketwired - Jun 2, 2016) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that the company will present at the Jefferies 2016 Healthcare Conference at 2 p.m. EDT on June 9, 2016 in New York City, NY.
HZNP: 18.89 (-0.40)
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen/esomeprazole) Delayed Release Tablets
Marketwire Canada - Wed Jun 01, 6:00AM CDT
Will Represent the Fifteenth U.S. Patent Listed in the Orange Book for VIMOVO
HZNP: 18.89 (-0.40), ARZ.TO: 4.56 (-0.07), ARLZ: 3.89 (+0.39)
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 98.20 (+1.20), HZNP: 18.89 (-0.40), ICPT: 169.72 (-3.31), ABBV: 66.94 (+0.71), ACOR: 25.13 (-0.15), BIOD: 0.41 (-0.03), XNPT: 7.07 (+0.05)
Horizon (HZNP) to Buy Global Rights to Actimmune, Stock Down
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:10AM CDT
Horizon Pharma (HZNP) will acquire global rights to Actimmune from Boehringer Ingelheim. The deal is expected to close by year end.
ANIP: 61.06 (+0.46), HZNP: 18.89 (-0.40), RTRX: 18.17 (+0.24), BMY: 76.19 (+1.38)
Horizon Pharma plc to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim International GmbH
Marketwire Canada - Thu May 19, 6:00AM CDT
Also Licenses Rights to Patents and Pending Applications Covering Methods for Treating Friedreich's Ataxia With Interferon Gamma-1b; Company Currently Owns the Rights to Interferon Gamma-1b Under the Trade Name ACTIMMUNE(R) in the United States, Canada and Japan
HZNP: 18.89 (-0.40)
Horizon Pharma plc to Participate in UBS Global Healthcare Conference
Marketwire Canada - Wed May 18, 4:45PM CDT
DUBLIN, IRELAND--(Marketwired - May 18, 2016) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that Timothy P. Walbert, chairman, president and chief executive officer, will present at the UBS Global Healthcare Conference at 11 a.m. EDT on May 25, 2016 in New York City, NY.
HZNP: 18.89 (-0.40)
Horizon Pharma plc Announces That Marilyn Vetter Honored as a 2016 Healthcare Businesswomen's Association Luminary
Marketwired - Thu May 12, 7:00AM CDT
DUBLIN, IRELAND--(Marketwired - May 12, 2016) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that Marilyn Vetter, vice president, government and public affairs, has been named a 2016 Healthcare Businesswomen's Association (HBA) Luminary. Marilyn will be honored today at the 27th annual Woman of the Year event in New York.
HZNP: 18.89 (-0.40)
Horizon Pharma plc Announces Settlement of PENNSAID(R) (diclofenac sodium topical solution) 2% w/w Patent Litigation With Teligent, Inc.
Marketwire Canada - Thu May 12, 6:00AM CDT
DUBLIN, IRELAND--(Marketwired - May 12, 2016) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that its affiliates have entered into a settlement and license agreement with Teligent, Inc. to resolve pending patent litigation involving PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID® 2%).
HZNP: 18.89 (-0.40), TLGT: 8.29 (+0.17)
Nuvo Pharmaceuticals™ Announces 2016 First Quarter Results
PR Newswire - Wed May 11, 4:00PM CDT
Revenue and gross margin increase - - Nuvo to Host Conference Call/Audio Webcast May 12th at 8:30 a.m. ET -
NRI.TO: 6.93 (-0.07), HZNP: 18.89 (-0.40)
